NewAmsterdam Pharma Company NV reports results for the quarter ended September 30 - Earnings Summary

• NewAmsterdam Pharma Company NV NAMS.OQ reported a quarterly adjusted loss of 61 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -18 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -51 cents to -18 cents per share.

• Revenue fell 98.8% to $348.00 thousand from a year ago; analysts expected $5.29 million.

• NewAmsterdam Pharma Company NV's reported EPS for the quarter was a loss of 61 cents​.

• The company reported a quarterly loss of $72.01 million.

• NewAmsterdam Pharma Company NV shares had risen by 28.4% this quarter and gained 42.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for NewAmsterdam Pharma Company NV is $44.00, about 17% above its last closing price of $36.53

This summary was machine generated from LSEG data November 5 at 02:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)